Drug updated on 7/25/2024
Dosage Form | Injection (intravenous; 300 mg/10 ml) |
Drug Class | CD20-directed cytolytic antibodies |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
- Indicated for the treatment of primary progressive MS in adults.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Ocrelizumab (Ocrevus) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults; it is also indicated for primary progressive MS in adults.
- A total of 9 studies from systematic reviews and meta-analyses were reviewed to gather information about ocrelizumab's safety and effectiveness compared to other drugs used for MS.
- In terms of efficacy, ocrelizumab was found superior or comparable to mitoxantrone, siponimod, natalizumab, and rituximab, among others, in delaying disease progression. It performed best on the Timed 25-Foot Walk test but had low certainty. For RMS patients specifically, it ranked highly alongside alemtuzumab and natalizumab regarding disability progression reduction.
- Safety profiles indicate that ocrelizumab has fewer serious adverse events compared to placebo when treating PMS. However, there were higher overall adverse event rates noted, particularly infusion-related reactions and infections, especially within PPMS populations as per Cochrane review findings.
- The drug showed decreasing IgG levels over time, which could be associated with increased infection risks according to studies focusing on immunoglobulin changes during treatment periods primarily involving RMS patients.
- According to ABN guidelines classification based on analysis conducted within UK standards, ocrelizumab was contextually placed under moderate-to-high efficacy categories concerning relapse rate reductions, highlighting its significant role among newer therapies available today.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Ocrevus (Ocrelizumab) Prescribing Information. | 2024 | Genentech USA, Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Ocrelizumab (Ocrevus®) protocol for the treatment of relapsing multiple sclerosis (RMS). | 2020 | Health Service Executive |
UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. | 2019 | Practical Neurology |